Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine versus tolterodine ER and placebo for overactive bladder
NL-OMON31014Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fesoterodine and tolterodine in overactive bladder (OAB) (4 arms), sponsored by Pfizer. Primary endpoint: Change in urgency urinary incontinence episodes per 24 hours. Planned start Jul 2007; status: withdrawn.
02
Drugs
fesoterodinetolterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON31014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31014.